Notice2024-25550
Joint Biomedical Laboratory Research and Development and Clinical Science Research and Development Services Scientific Merit Review Board, AMENDED, Notice of Meeting
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
November 4, 2024
Issuing agencies
Veterans Affairs Department
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 213 (Monday, November 4, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 213 (Monday, November 4, 2024)]
[Notices]
[Page 87727]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-25550]
-----------------------------------------------------------------------
DEPARTMENT OF VETERANS AFFAIRS
Joint Biomedical Laboratory Research and Development and Clinical
Science Research and Development Services Scientific Merit Review
Board, AMENDED, Notice of Meeting
The Department of Veterans Affairs (VA) gives notice under the
Federal Advisory Committee Act, 5 U.S.C. ch.10, that a meeting of the
Joint Biomedical Laboratory Research and Development and Clinical
Science Research and Development Services Scientific Merit Review Board
will be held January 7, 2025, via WebEx. The meeting will be held
between 3 and 5 p.m. EDT. The meeting will be closed to the public from
3:30-5 p.m. EDT for scientific review and the discussion, examination,
and reference to the research applications. Discussions will involve
reference to staff and consultant critiques of research proposals.
Discussions will deal with scientific merit of each proposal and
qualifications of personnel conducting the studies, the disclosure of
which would constitute a clearly unwarranted invasion of personal
privacy. Additionally, premature disclosure of research information
could significantly obstruct implementation of proposed agency action
regarding the research proposals. As provided by Public Law 92-463
subsection 10(d), and as amended by Public Law 94-409, closing the
committee meeting is in accordance with 5 U.S.C. 552b(c)(6) and (9)(B).
The objective of the Board is to provide for the fair and equitable
selection of the most meritorious research projects for support by VA
research funds and to offer advice for research program officials on
program priorities and policies. The ultimate objective of the Board is
to ensure the high quality and mission relevance of VA's legislatively
mandated Biomedical Laboratory and Clinical Science Research and
Development programs.
Board members advise the Directors of the Biomedical Laboratory and
Clinical Sciences Research Services and the Chief Research and
Development Officer on the scientific and technical merit, mission
relevance, and protection of human subjects of Biomedical Laboratory
and Clinical Sciences Research and Development proposals. The Board
does not consider grants, contracts, or other forms of extramural
research.
Members of the public may attend the open portion of the meeting.
The time limited agenda does not enable public comments or
presentations. To attend the open portion of the meeting (3-3:30 p.m.
EDT), the public may join by dialing the phone number 1-404-397-1596
and entering the meeting number (access code): 2823 274 3705. These
stakeholders must notify the DFO of their intention to speak to the
committee.
Written public comments must be sent to Michael R. Burgio, Ph.D.,
Designated Federal Officer, Advisory Committee Management Office, 811
Vermont Avenue NW, Room 4342A, Washington, DC 20006, or to
<a href="/cdn-cgi/l/email-protection#337e5a505b52565f1d714641545a5c7345521d545c45"><span class="__cf_email__" data-cfemail="1f52767c777e7a73315d6a6d7876705f697e31787069">[email protected]</span></a>, at least five days before the meeting. The
written public comments will be shared with the Board members. The
public may not attend the closed portion of the meeting as disclosure
of research information could significantly obstruct implementation of
proposed agency action regarding the research proposals (per Pub. L.
92-463 subsection 10(d), as amended by Public Law 94-409, closing the
committee meeting is in accordance with 5 U.S.C. 552b(c)(6) and (9)(B).
Dated: October 29, 2024.
LaTonya L. Small,
Federal Advisory Committee Management Officer.
[FR Doc. 2024-25550 Filed 11-1-24; 8:45 am]
BILLING CODE 8320-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on November 4, 2024.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.